Approval · Notice of Compliance 28798 · 2022
LAMISIL: Notice of Compliance 28798
Issued August 19, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28798
- Date
- August 19, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph to the 2020 Master PM template format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LAMISIL | Not yet assigned | — |
Medicinal ingredients
- TERBINAFINE HCL 1 PER
- TERBINAFINE HCL 250 MG per TAB